SCHEMBL20132541

SCHEMBL20132541

CC(C)C1CCCc2cccnc2C1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 9/20 0.42
DRD2 P14416 2/20 0.40
CYP19A1 P11511 1/20 0.40
DRD3 P35462 1/20 0.40
IDH1 O75874 2/20 0.38
GRIN1 Q05586 3/20 0.36
GRIN2B Q13224 3/20 0.36
GRM4 Q14833 1/20 0.36
CYP1A1 P04798 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2E1 P05181 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C8 P10632 1/20 0.35
CYP2A6 P11509 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP4B1 P13584 1/20 0.35
CYP2B6 P20813 1/20 0.35
CYP3A5 P20815 1/20 0.35
CYP2A7 P20853 1/20 0.35
CYP3A7 P24462 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12907276 0.90 DRD2 (0.41) CYP2D6DRD2CYP19A1DRD3IDH1
SCHEMBL8376129 0.82 DRD2 (0.41) CYP2D6DRD2DRD3IDH1GRIN1
SCHEMBL2669660 0.82 DRD2 (0.41) CYP2D6DRD2DRD3IDH1GRIN1
SCHEMBL1615480 0.81 DRD2 (0.51) CYP2D6DRD2CYP19A1DRD3IDH1
SCHEMBL25159078 0.78 CYP19A1 (0.35) CYP19A1
SCHEMBL2463278 0.76 CYP2D6 (0.44) CYP2D6DRD2CYP19A1DRD3IDH1
SCHEMBL20000788 0.75 CYP2D6 (0.42) CYP2D6DRD2CYP19A1DRD3IDH1
SCHEMBL30666578 0.71 DRD2 (0.44) CYP2D6DRD2CYP19A1DRD3IDH1
SCHEMBL14452400 0.71 DRD2 (0.41) CYP2D6DRD2DRD3IDH1GRIN1
SCHEMBL12891737 0.71 DRD2 (0.44) CYP2D6DRD2CYP19A1DRD3IDH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230123591-A1 TGF-ß INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2023-04-20 US disclosed
US-20180127426-A1 TGF-Beta Inhibitors MIDCAP FINANCIAL TRUST 2018-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180127426-A1 TGF-Beta Inhibitors TGFBR1, TGFBR2, TGFB1 CYP2D6 3892/4885DRD2 4531/4885CYP19A1 1851/4885
US-20230123591-A1 TGF-ß INHIBITORS TGFBR1, TGFBR2, TGFB1 CYP2D6 3120/4885DRD2 4551/4885CYP19A1 1600/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.